Tela Bio Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Tela Bio Inc's ROI in the second quarter of 2026?
Tela Bio Inc recorded a cumulative net loss of $-41 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -81.69%.

Within the Healthcare sector 590 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3944, from total ROI ranking in the first quarter of 2026 at 4562.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-6.79 %	-2.1 %	3.94 %	12.89 %	-7.92 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	42	52	63	45	48
Return On Investment (TTM)	-81.69 %	-76.4 %	-71.5 %	-69.4 %	-75.38 %
TELA's Overall Ranking	# 3944	# 4562	# 4006	# 4084	# 4161
Seq. Investment Change TTM	-3.33 %	-3.98 %	-3.35 %	3.91 %	1.53 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-41	-40	-39	-39	-41

TELA Company Profile >> Back to TELA Roi Comparisons >> See Annual TELA Return On Investment

Return On Investment TELA's Ranking
Within:	No.
Industry	# 140
Sector	# 591
Overall	# 3944

Return On Investment Statistics
High	Average	Low
-23.32 %	-68.74 %	-146.29 %
(Jun 30 2020)		(Sep 30 2019)

News about Tela Bio Inc Return on Investment ROI

TELA Bio Attracts Prominent Surgeon to Optimize Clinical Outcomes in Plastic and Reconstructive Surgery amidst Financial Challenges

April 8, 2024

TELA Bio s decision to bring on board Dr. Langstein is a strategic move aimed at leveraging his expertise to improve clinical outcomes in the field of plastic and reconstructive surgery. With his extensive experience and knowledge, Dr. Langstein will work closely with other surgeons to identify innovative techniques and develop strategies that contribute to better patient results.
Dr. Langstein s appointment comes at a crucial time for TELA Bio. The company recorded a significant net loss of $47 million during the 12 months ending in the fourth quarter of 2023. This negative return on investment (ROI) stood at -72.13%, indicating a substantial financial setback.

TELA Bio Grants Restricted Stock Units to New Hires, Aims to Overcome Financial Challenges

February 23, 2024

TELA Bio Approves Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has recently announced that it has approved inducement grants for five newly-hired employees. The Compensation Committee of the Board of Directors of TELA Bio granted restricted stock units covering 5,800 shares of its common stock to these employees, with a grant date of February 21, 2024.
These inducement grants were made in accordance with the Nasdaq Rule 5635(c)(4) exception, as part of each individual s employment compensation. The grants were provided to encourage and incentivize these employees to accept employment with TELA Bio.

Financial Statements
Tela Bio Inc's II. Quarter Investments	$ 42 Millions	TELA's Balance sheet
Tela Bio Inc's II. Quarter Income	$ -11 Millions	Quarterly TELA's Income Statement
TELA's Income by Division		See TELA's Income by Division

TELA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	63	71	61	55	52
Y / Y Investment Growth	-10.61 %	16.19 %	10.15 %	6.7 %	-34.92 %
Net Income in Millions	-39	-38	-47	-44	-33
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-61.21 %	-53.32 %	-76.4 %	-79.88 %	-64.03 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TELA's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TELA's Competitors
Subscribers only: Roi for Tela Bio Inc's Suppliers
Subscribers only: Return On Investment for TELA's Customers

Other Ratios
TELA's Roa	TELA's Inventory Turnover Ratio	TELA's Growth Rates	TELA's Dividend Statistics
	TELA's Profitability Ratios	TELA's Asset Turnover Ratio	TELA's Dividend Growth
TELA's Roe	TELA's Valuation Ratios	TELA's Financial Strength Ratios	TELA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:38:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.